Skip to main content

Advertisement

SpringerLink
Log in

Mesenchymal Stem Cells as a Potential Therapeutic Tool for Spinocerebellar Ataxia

  • Review
  • Published:
The Cerebellum Aims and scope Submit manuscript

Abstract

Spinocerebellar ataxia (SCA) is a devastating progressive neurodegenerative disorder, for which no effective treatments have been developed. However, some studies have shown that an intracerebellar or intrathecal injection of mesenchymal stem cells (MSCs) was partially effective in some genetic mouse models of cerebellar ataxia such as SCA1 and Lurcher mutant. MSCs likely exert their therapeutic efficacy by secreting innate factors to induce neuronal growth and synaptic connection and reduce apoptosis. In this review, we introduce the therapeutic influence of MSCs on each mouse model for cerebellar ataxia and the possible mechanisms underlying the action of MSCs. We also introduce studies on the safety and effectiveness of umbilical cord MSCs for patients with SCA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Orr HT. Cell biology of spinocerebellar ataxia. J Cell Biol. 2012;197:167–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum. 2005;4:2–6.

    Article  CAS  PubMed  Google Scholar 

  3. Taroni F, DiDonato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci. 2004;5:641–55.

    Article  CAS  PubMed  Google Scholar 

  4. Matilla-Duenas A, Goold R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106–14.

    Article  CAS  PubMed  Google Scholar 

  5. Robitaille Y, Schut L, Kish SJ. Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol. 1995;90:572–81.

    Article  CAS  PubMed  Google Scholar 

  6. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151–5.

    Article  CAS  PubMed  Google Scholar 

  7. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995;82:937–48.

    Article  CAS  PubMed  Google Scholar 

  8. Clark HB, Burright EN, Yunis WS, Larson S, Wilcox C, Hartman B, et al. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci. 1997;17:7385–95.

    CAS  PubMed  Google Scholar 

  9. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10:816–20.

    Article  CAS  PubMed  Google Scholar 

  10. Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci. 2008;11:1137–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Hirai H. Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors. Cerebellum. 2008;7:273–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sawada Y, Kajiwara G, Iizuka A, Takayama K, Shuvaev AN, Koyama C, et al. High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo. Cerebellum. 2010;9:291–302.

    Article  CAS  PubMed  Google Scholar 

  13. Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S, et al. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008;9:393–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Chintawar S, Hourez R, Ravella A, Gall D, Orduz D, Rai M, et al. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J Neurosci. 2009;29:13126–35.

    Article  CAS  PubMed  Google Scholar 

  15. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol. 2010;223:229–37.

    Article  CAS  PubMed  Google Scholar 

  16. Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res. 2003;73:778–86.

    Article  CAS  PubMed  Google Scholar 

  17. Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M, et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia. 2005;49:407–17.

    Article  PubMed  Google Scholar 

  18. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–34.

    Article  CAS  PubMed  Google Scholar 

  19. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

    Article  CAS  PubMed  Google Scholar 

  20. Woodbury D, Reynolds K, Black IB. Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res. 2002;69:908–17.

    Article  CAS  PubMed  Google Scholar 

  21. Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem. 2003;89:1235–49.

    Article  CAS  PubMed  Google Scholar 

  22. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy. 2003;5:362–9.

    Article  PubMed  Google Scholar 

  23. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103:1669–75.

    Article  CAS  PubMed  Google Scholar 

  24. Paul G, Anisimov SV. The secretome of mesenchymal stem cells: potential implications for neuroregeneration. Biochimie. 2013;95:2246–56.

    Article  CAS  PubMed  Google Scholar 

  25. Jones J, Jaramillo-Merchan J, Bueno C, Pastor D, Viso-Leon M, Martinez S. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol Dis. 2010;40:415–23.

    Article  PubMed  Google Scholar 

  26. Zuo J, De Jager PL, Takahashi KA, Jiang W, Linden DJ, Heintz N. Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene. Nature. 1997;388:769–73.

    Article  CAS  PubMed  Google Scholar 

  27. Matsuura S, Shuvaev AN, Iizuka A, Nakamura K, Hirai H. Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1. Cerebellum. 2014;13:323–30.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang MJ, Sun JJ, Qian L, Liu Z, Zhang Z, Cao W, et al. Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice. Brain Res. 2011;1402:122–31.

    Article  CAS  PubMed  Google Scholar 

  29. Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther. 2012;7:407–14.

    Article  CAS  PubMed  Google Scholar 

  30. Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington’s disease. Mol Neurobiol. 2012;45:87–98.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets. 2009;8:110–23.

    Article  CAS  PubMed  Google Scholar 

  33. Le Blanc K. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy. 2006;8:559–61.

    Article  PubMed  Google Scholar 

  34. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010;5:933–46.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 2010;62:1167–74.

    Article  CAS  PubMed  Google Scholar 

  36. Aizman I, Tate CC, McGrogan M, Case CC. Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth. J Neurosci Res. 2009;87:3198–206.

    Article  CAS  PubMed  Google Scholar 

  37. Gahan PB, Stroun M. The virtosome—a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct. 2010;28:529–38.

    Article  CAS  PubMed  Google Scholar 

  38. Gerdes HH, Carvalho RN. Intercellular transfer mediated by tunneling nanotubes. Curr Opin Cell Biol. 2008;20:470–5.

    Article  CAS  PubMed  Google Scholar 

  39. Simons M, Raposo G. Exosomes—vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.

    Article  CAS  PubMed  Google Scholar 

  40. Meyerrose TE, Roberts M, Ohlemiller KK, Vogler CA, Wirthlin L, Nolta JA, et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells. 2008;26:1713–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Olson SD, Kambal A, Pollock K, Mitchell GM, Stewart H, Kalomoiris S, et al. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington’s disease affected neuronal cells for reduction of huntingtin. Mol Cell Neurosci. 2012;49:271–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Liu J, Han D, Wang Z, Xue M, Zhu L, Yan H, et al. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy. 2013;15:185–91.

    Article  PubMed  Google Scholar 

  43. Dongmei H, Jing L, Mei X, Ling Z, Hongmin Y, Zhidong W, et al. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Cytotherapy. 2011;13:913–7.

    Article  PubMed  Google Scholar 

  44. Jin JL, Liu Z, Lu ZJ, Guan DN, Wang C, Chen ZB, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res. 2013;10:11–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

There are no potential conflicts of interest in the content of this paper.

Author information

Authors and Affiliations

  1. Department of Neurophysiology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Kazuhiro Nakamura, Nana Suto, Serina Matsuura & Hirokazu Hirai

  2. Orthopedic Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Tokue Mieda

Authors
  1. Kazuhiro Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tokue Mieda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nana Suto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serina Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirokazu Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirokazu Hirai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, K., Mieda, T., Suto, N. et al. Mesenchymal Stem Cells as a Potential Therapeutic Tool for Spinocerebellar Ataxia. Cerebellum 14, 165–170 (2015). https://doi.org/10.1007/s12311-014-0604-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12311-014-0604-1

Keywords

Search

Navigation